Research Article

Resveratrol Treatment Is Associated with Lipid Regulation and Inhibition of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) in Rabbits Fed a High-Fat Diet

Table 3

Biochemical analysis of rabbits from RFG (n = 8) before the beginning of the treatment with fat diet and at the end of the 3-month fat diet.

Baseline (n = 8)After 3 months (n = 8)t value

Weight(kg) (NDG)0.96 ± 0.052.90 ± 0.08−73.655<0.001
Weight (kg) (FDG)0.99 ± 0.082.98 ± 0.15−49.925<0.001
Weight (kg) (RFG)1.01 ± 0.082.96 ± 0.07−39.000<0.001
ALT (NDG)43.20 ± 9.6544.81 ± 7.95−0.7810.461
ALT (FDG)41.22 ± 8.8350.86 ± 24.53−1.1720.280
ALT (RFG)44.76 ± 12.8061.06 ± 20.26−2.1600.068
AST (NDG)36.38 ± 8.6140.51 ± 6.46−2.4900.042
AST (FDG)33.73 ± 5.9184.32 ± 54.94−2.6390.033
AST (RFG)34.88 ± 4.9877.91 ± 24.54−5.5870.001
CREA (NDG)67.94 ± 8.3977.38 ± 10.45−7.002<0.001
CREA (FDG)64.72 ± 6.27111.92 ± 11.38−10.794<0.001
CREA (RFG)65.75 ± 9.69127.63 ± 10.84−12.390<0.001
TG (NDG)0.63 ± 0.200.62 ± 0.210.0860.934
TG (FDG)0.50 ± 0.160.90 ± 0.42−2.2300.061
TG (RFG)0.48 ± 0.070.76 ± 0.28−2.9860.020
TC (NDG)1.94 ± 0.212.19 ± 0.30−2.9190.022
TC (FDG)1.88 ± 0.2830.32 ± 5.74−14.078<0.001
TC (RFG)1.99 ± 0.4311.84 ± 2.78−9.275<0.001
HDL (NDG)0.93 ± 0.191.03 ± 0.20−3.3590.012
HDL (FDG)0.94 ± 0.253.28 ± 1.61−3.8150.007
HDL (RFG)0.93 ± 0.171.58 ± 0.35−4.8800.002
LDL (NDG)0.84 ± 0.220.91 ± 0.22−1.2700.245
LDL (FDG)0.95 ± 0.1216.45 ± 3.16−13.489<0.001
LDL (RFG)0.80 ± 0.276.23 ± 1.53−9.221<0.001
Lp-PLA2# (NDG)461.50 ± 89.57520.14 ± 51.55−1.9300.095
Lp-PLA2# (FDG)525.48 ± 32.501928.88 ± 385.78−10.090<0.001
Lp-PLA2# (RFG)494.88 ± 32.56953.20 ± 96.66−12.816<0.001

#The test result of homogeneity of variance was , and Dunnett’s T method was used for multiple comparison of value correction, while the Bonferroni method was used for the other indicators. NDG, normal diet group; FDG, fat diet group; RFG, fat diet with resveratrol; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CREA, creatinine; TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp-PLA2, lipoprotein-associated phospholipase A2.